Advisory Committee On NRT Indications Appears Likely Following Workshop
This article was originally published in The Tan Sheet
Executive Summary
Speakers at a workshop on nicotine-replacement therapy point abroad for guidance on expanding indications for smoking-cessation products as an FDA official says the agency likely will put the question before an advisory committee.
You may also be interested in...
FDA Ignores Tobacco Harm Reduction As Therapeutic Option – Experts
FDA's tobacco product policies impede development of alternatives to smoking-cessation products with utility for harm reduction, according to an expert panel.
Smoking Cessation Growth Opportunities Lay With Employers, Health Care Reform
Many employers still hold a short-sighted view of the cost of smoking cessation therapies, panelists at an American University webinar said Nov. 16.
CDER-Tobacco Center Joint Meeting Could Signal Talks On NRT Indications
FDA's work to implement its tobacco control authorities includes planning a joint meeting of its drug and tobacco centers to address issues such as the extended use of nicotine replacement therapy